Oklo at $43: The "It's Worth $75" Target Is a 2028 Option, Not a Valuation

A stock at $43 against an analyst target near $75 sounds simple to value. Oklo (OKLO) is the opposite of simple, because there is nothing to value in the usual sense. The company reported Q2 revenue of just $1.2 million and a year-to-date net loss of $81.6 million, and the nuclear business that is supposed to be worth a fortune has not yet sold a single megawatt. Yet Oklo commands a market cap near $7.9 billion. The gap between those two facts is the whole article.

So what do we put our hand on first? I start with the multiples, because they are the honest place to begin. Trailing P/E is negative 51.8, forward P/E is negative 114.8, and the PEG ratio comes back at 0.35 — a number that is mathematically a "value" and practically meaningless, because PEG divides price by a growth rate that is negative or undefined at the earnings level. The lesson is the one that keeps getting lost with nuclear stocks: Oklo has no earnings multiple to look at at all. A stock with no earnings is not "cheap" or "expensive" on a P/E basis. It is priced as a probability, and the price is a bet.

That is the reframe I want to land before the numbers. Oklo does not build and sell reactors. It is a build-own-operate business — it funds, builds, owns, and runs the plants, then sells the electricity. That is why there is no revenue: the plants are not producing yet. Aurora-INL, the flagship reactor at Idaho National Laboratory, is targeted to start up in 2028. The isotope facility in Groves, Texas, reached first criticality just over 11 months after groundbreaking, and fuel deliveries for the initial core are not expected until 2029. The $1.2 million in Q2 revenue was not nuclear at all — it came from two small acquisitions the company closed during the quarter.

Now let me put a number on what the market is actually paying for. Take the $7.9 billion market cap and subtract the roughly $3 billion in cash and marketable securities the company reported at the end of Q2 — $1.6 billion in cash and $1.4 billion in securities. What is left is about $4.9 billion. That is the entire value the market assigns to the future: the Aurora design, the 1.2-gigawatt Ohio campus, the customer pipeline, and the fuel-recycling story, all of it. For scale, NuScale Power (SMR) — Oklo's only true peer, also a pre-revenue reactor builder — is valued at $4.6 billion with no cash cushion to subtract. Oklo is essentially selling you a $4.9 billion option on nuclear deployment by 2028.

The 78% drawdown from the $193.84 high is not the company failing. It is that option being repriced — from the euphoria of the late-2025 AI-and-nuclear run, when Oklo gained well over 500% for the year, back toward a number the market thinks is realistic. The price move tells you about sentiment. It tells you almost nothing about whether the plant gets built.

Here is where the comparison set actually helps, because it shows you which side of nuclear you are buying. The sector splits in two. On the supply side, Cameco (CCJ) sits at a $43.75 billion market cap on a 173x P/E, BWX Technologies (BWXT) at $14.35 billion on a 40x P/E, and Centrus (LEU) at 75x — all of them with real earnings and real revenue to anchor the multiples. On the build side, Oklo and NuScale have none of that. You cannot rank them against Cameco on a P/E and get a useful answer; they are different questions. Cameco is a commodity story you can value off earnings. Oklo is a "does Aurora start up in 2028, and does the customer show up" story, and the only honest way to price it is as that.

AInvest's aggregate signal labels the stock a Buy, and Wall Street targets cluster between about $76 and $87. I would not treat either of those as a floor. The consensus rating is a label, and the targets are 2028 option prices — which is exactly why they sit roughly 75% to 100% above today's price, and why the low end of the street can drop into the teens. A target is not a value.

The risk is a single, honest sentence: if Aurora-INL does not start up on time, or the 1.2-gigawatt Kiewit-built campus meant to supply Meta does not convert from a memorandum of understanding into a signed, funded contract, the $4.9 billion the market is paying for the future goes down fast. The cushion that keeps this from being a near-term collapse is the cash. Oklo has raised roughly $1.9 billion through at-the-market equity in 2026 alone, and its 2026 spend — operating burn of $120 to $150 million plus property, plant, and equipment of $400 to $500 million — leaves that $3 billion runway lasting several years. This is a slow-burn bet, not a going-concern problem.

So where does it fit, and how do you size it? As a portfolio role, Oklo belongs in the satellite portion of a growth sleeve — a concentrated, long-duration bet on nuclear deployment execution that has a multi-year horizon. Size it the way you size anything with a binary-ish payoff: small enough that a total loss of the position does not change your financial life, because the "down side" of this name is the option going to zero, not the stock dropping 20%. If you want nuclear exposure without the execution risk, the barbell is to pair a position like Oklo with the earnings side of the trade — the fuel and uranium suppliers that have revenue today. The two express the same macro belief (more nuclear, powered by AI data centers) at completely different risk.

The thing I would not do is chase the target. The stock is down 78% and the market has already taken the optimism out of it. What actually moves the thesis is not the price, not the rating, and not the $75 number — it is the Aurora-INL 2028 startup milestone and the Kiewit/Meta Ohio deal converting into a real contract. Watch those two. Everything else is noise the market will argue about until the first plant is online.